Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | MAOA | P21397 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
| ▸ | PTPRC | P08575 | 2/20 | 0.37 |
| ▸ | GAA | P10253 | 2/20 | 0.36 |
| ▸ | CA12 | O43570 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.34 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | TET2 | Q6N021 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | TERT | O14746 | 1/20 | 0.33 |
| ▸ | APLNR | P35414 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL715683 | 0.98 | RECQL (0.39) | RECQLMAOAMAOBPTPRCGAA | |
| SCHEMBL13292141 | 0.96 | RECQL (0.38) | RECQLMAOAMAOBPTPRCGAA | |
| SCHEMBL6575441 | 0.96 | RECQL (0.38) | RECQLMAOAMAOBPTPRCGAA | |
| Hydrochloric Acid SCHEMBL9087860 | 0.94 | RECQL (0.37) | RECQLMAOAMAOBPTPRCGAA | |
| SCHEMBL27601805 | 0.87 | RECQL (0.33) | RECQLMAOAMAOBPTPRCHRH3 | |
| SCHEMBL29004075 | 0.85 | RECQL (0.36) | RECQLMAOAMAOBGAACA12 | |
| SCHEMBL1119918 | 0.84 | RECQL (0.37) | RECQLMAOAMAOBGAACA12 | |
| SCHEMBL7376338 | 0.83 | RECQL (0.41) | RECQLMAOAMAOBPTPRCGAA | |
| SCHEMBL29706242 | 0.82 | MAOA (0.35) | RECQLMAOAMAOBGAACA12 | |
| Hydrochloric Acid SCHEMBL7991659 | 0.81 | MLYCD (0.39) | RECQLMAOAMAOBGAACA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 70 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4676483-A1 | IMPROVED LINKER-PAYLOADS FOR ANTIBODY CONJUGATION, PHARMACEUTICAL COMPOSITIONS AND APPLICATIONS THEREOF | OBI Pharma, Inc. (TW) | 2026-01-14 | — | — | EP | disclosed |
| EP-4637748-A2 | PNU ANTHRACYCLINE-DERIVED LINKER-PAYLOADS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | Merck Sharp & Dohme LLC (US) | 2025-10-29 | — | — | EP | disclosed |
| EP-4608453-A1 | EXATECAN-DERIVED ADC LINKER-PAYLOADS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | Merck Sharp & Dohme LLC (US) | 2025-09-03 | — | — | EP | disclosed |
| EP-4558511-A2 | GLUCOCORTICOID RECEPTOR AGONISTS AND CONJUGATES THEREOF | Firefly Bio, Inc. (US) | 2025-05-28 | — | — | EP | disclosed |
| US-20250129021-A1 | SMALL MOLECULE PROTEIN SYNTHESIS MODULATORS | Interdict Bio, Inc. (US) | 2025-04-24 | — | — | US | disclosed |
| EP-4541796-A1 | EXATECAN DERIVATIVES AND USE THEREOF | Hangzhou Adcoris Biopharma Co., Ltd (CN) | 2025-04-23 | — | — | EP | disclosed |
| WO-2025064718-A1 | SMALL MOLECULE PROTEIN SYNTHESIS MODULATORS | Interdict Bio, Inc. (US) | 2025-03-27 | — | — | WO | disclosed |
| WO-2025064733-A1 | IMPROVED LINKER-PAYLOADS FOR ANTIBODY CONJUGATION, PHARMACEUTICAL COMPOSITIONS AND APPLICATIONS THEREOF | OBI PHARMA, INC. (TW) | 2025-03-27 | — | — | WO | disclosed |
| EP-4489792-A1 | PHENYL MALEIMIDE LINKER AGENTS | Firefly Bio, Inc. (US) | 2025-01-15 | — | — | EP | disclosed |
| CN-118434765-A | BCMA monoclonal antibodies and antibody-drug conjugates | 杭州多禧生物科技有限公司 | 2024-08-02 | — | — | CN | disclosed |
| WO-2011130613-A1 | TARGETED PYRROLOBENZODIAZAPINE CONJUGATES | SEATTLE GENETICS, INC. (US) | 2011-10-20 | — | — | WO | disclosed |
| CN-1886114-B | Parakeratosis inhibitor and composition for external use on skin | SHISEIDO CO LTD | 2011-08-10 | — | — | CN | disclosed |
| CN-100482285-C | Targeting of tumor vasculature using radiolabelled antibody l19 against fibronectin ED-B | PHILOGEN S P A SCHERING AG (IT) | 2009-04-29 | — | — | CN | disclosed |
| CN-1886114-A | Parakeratosis inhibitor and composition for external use on skin | SHISEIDO CO LTD (JP) | 2006-12-27 | — | — | CN | disclosed |
| CN-1849144-A | Targeting of tumor vasculature using radiolabelled antibody l19 against fibronectin ED-B | PHILOGEN SPA (IT) | 2006-10-18 | — | — | CN | disclosed |
| EP-0649414-B1 | OPIOID DIARYLMETHYLPIPERAZINES AND PIPERIDINES | ARDENT PHARMACEUTICALS INC (US) | 2003-04-16 | — | — | EP | disclosed |
| US-5854249-A | Opioid diarylmethylpiperazines and piperidines | DELTA PHARMACEUTICALS, INC. (US) | 1998-12-29 | — | — | US | disclosed |
| US-5658908-A | RECEPTOR BINDING SPECIES FOR MEDIATING ANALGESIA, COMBATTING DRUG ADDICTION, DRUG OVERDOSE | DELTA PHARMACEUTICALS, INC. (US) | 1997-08-19 | — | — | US | disclosed |
| EP-0649414-A1 | OPIOID DIARYLMETHYLPIPERAZINES AND PIPERIDINES | THE WELLCOME FOUNDATION LIMITED (GB) | 1995-04-26 | — | — | EP | disclosed |
| WO-1993015062-A1 | OPIOID DIARYLMETHYLPIPERAZINES AND PIPERIDINES | THE WELLCOME FOUNDATION LIMITED (GB) | 1993-08-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250129021-A1 | SMALL MOLECULE PROTEIN SYNTHESIS MODULATORS | MYC, KRAS, NRAS | RECQL 849/4885MAOA 4755/4885MAOB 4535/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.